HEARTCARE-B (06609) surged nearly 7% in late trading. As of press time, the stock was up 6.8% to HK$64.4, with turnover reaching HK$25.0596 million.

On the news front, HeartCare Medical recently announced its interim results. In the first half of the year, the company achieved operating revenue of RMB 186 million, representing a 44.4% year-on-year increase. Net profit attributable to shareholders reached RMB 50.9 million, successfully turning from loss to profit and smoothly crossing the break-even point.

As noted in previous analysis, with hemorrhagic products beginning to contribute quantitatively in the first half and the ischemic product matrix continuing to iterate, the continuously improving "procedural closed loop" for access/hemostasis has become the main engine driving HeartCare Medical's revenue growth in the first half.

Furthermore, while accelerating efforts to "increase revenue and reduce costs," HeartCare Medical has been further enhancing its integrated R&D-production-sales innovation ecosystem in recent years, solidifying the foundation for the company's transition from "structural foundation" to "commercial realization."

As of now, the company has obtained NMPA approval for 32 device products, FDA approval for three device products, and CE marking for one product. The product pipeline extensively covers acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and interventional access.